Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

High-titer convalescent plasma was compared with placebo in older adult patients within the first 3 days after the onset of symptoms of Covid-19 and documented SARS-CoV-2 infection. Disease progression was approximately half as common in patients who received convalescent plasma (16%) as in those wh...

Full description

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 384; no. 7; pp. 610 - 618
Main Authors: Libster, Romina, Pérez Marc, Gonzalo, Wappner, Diego, Coviello, Silvina, Bianchi, Alejandra, Braem, Virginia, Esteban, Ignacio, Caballero, Mauricio T, Wood, Cristian, Berrueta, Mabel, Rondan, Aníbal, Lescano, Gabriela, Cruz, Pablo, Ritou, Yvonne, Fernández Viña, Valeria, Álvarez Paggi, Damián, Esperante, Sebastián, Ferreti, Adrián, Ofman, Gastón, Ciganda, Álvaro, Rodriguez, Rocío, Lantos, Jorge, Valentini, Ricardo, Itcovici, Nicolás, Hintze, Alejandra, Oyarvide, M. Laura, Etchegaray, Candela, Neira, Alejandra, Name, Ivonne, Alfonso, Julieta, López Castelo, Rocío, Caruso, Gisela, Rapelius, Sofía, Alvez, Fernando, Etchenique, Federico, Dimase, Federico, Alvarez, Darío, Aranda, Sofía S, Sánchez Yanotti, Clara, De Luca, Julián, Jares Baglivo, Sofía, Laudanno, Sofía, Nowogrodzki, Florencia, Larrea, Ramiro, Silveyra, María, Leberzstein, Gabriel, Debonis, Alejandra, Molinos, Juan, González, Miguel, Perez, Eduardo, Kreplak, Nicolás, Pastor Argüello, Susana, Gibbons, Luz, Althabe, Fernando, Bergel, Eduardo, Polack, Fernando P
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 18-02-2021
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:High-titer convalescent plasma was compared with placebo in older adult patients within the first 3 days after the onset of symptoms of Covid-19 and documented SARS-CoV-2 infection. Disease progression was approximately half as common in patients who received convalescent plasma (16%) as in those who received placebo (31%).
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
The Fundación INFANT–COVID-19 Group members are listed in the Supplementary Appendix, available with the full text of this article at NEJM.org.
Drs. Libster and Pérez Marc contributed equally to this article.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMoa2033700